Holen Sie sich die Stockscreener-App
3.18
3.91%
0.11
Schlusskurs vom Vortag:
$3.07
Offen:
$3.07
24-Stunden-Volumen:
50,655
Relative Volume:
0.39
Marktkapitalisierung:
$43.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-70.20M
KGV:
-0.071
EPS:
-44.82
Netto-Cashflow:
$-50.66M
1W Leistung:
-6.73%
1M Leistung:
+1.92%
6M Leistung:
+20.38%
1J Leistung:
-67.65%
1-Tages-Spanne:
$2.925
$3.27
1-Wochen-Bereich:
$2.925
$3.4999
52-Wochen-Spanne:
$1.70
$10.07
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Firmenname
Onkure Therapeutics Inc
Sektor
Branche
Telefon
(720) 307-2892
Adresse
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Vergleichen Sie OKUR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
3.18 | 41.59M | 0 | -70.20M | -50.66M | -44.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.66 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.51 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
842.70 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.52 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.53 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-30 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-05 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-10 | Eingeleitet | Oppenheimer | Outperform |
| 2023-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-15 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-12-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | Eingeleitet | William Blair | Outperform |
| 2023-08-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-07-03 | Eingeleitet | BofA Securities | Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-01-27 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-12-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-22 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-05-04 | Eingeleitet | Jefferies | Buy |
| 2021-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2021-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Onkure Therapeutics Inc Aktie (OKUR) Neueste Nachrichten
Portfolio Update: Why OnKure Therapeutics Inc stock is a must watch in 2025Quarterly Profit Summary & AI Based Trade Execution Alerts - moha.gov.vn
Acorn Capital Advisors LLC Grows Position in OnKure Therapeutics, Inc. $OKUR - Defense World
Why OnKure Therapeutics Inc stock could rally in 2025Weekly Volume Report & Reliable Entry Point Trade Alerts - moha.gov.vn
Ready to Jump After Recent Trade: OnKure Therapeutics Inc (OKUR) - Setenews
Why OnKure Therapeutics Inc. stock could outperform in 2025CPI Data & Weekly Breakout Stock Alerts - Newser
OnKure Therapeutics (OKUR) Stock Analysis Report | Financials & Insights - Benzinga
Will OnKure Therapeutics Inc. stock sustain high P E ratiosMarket Performance Recap & Capital Efficient Trade Techniques - Newser
Published on: 2025-11-27 20:24:24 - BỘ NỘI VỤ
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Why OnKure Therapeutics Inc. stock is considered a top pick2025 Breakouts & Breakdowns & Verified Short-Term Plans - BỘ NỘI VỤ
[424B3] OnKure Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
What margin trends mean for OnKure Therapeutics Inc. stockGDP Growth & Weekly Chart Analysis and Guides - newser.com
Why OnKure Therapeutics Inc. stock is a value investor pickJuly 2025 Trends & Short-Term Swing Trade Alerts - newser.com
How rising interest rates impact OnKure Therapeutics Inc. stockPortfolio Value Summary & Verified Swing Trading Watchlist - newser.com
Will OnKure Therapeutics Inc. stock remain a Wall Street favorite2025 Analyst Calls & Long-Term Safe Investment Plans - newser.com
How OnKure Therapeutics Inc. stock reacts to inflationary pressuresWeekly Profit Summary & Long Hold Capital Preservation Tips - newser.com
Institutional scanner results for OnKure Therapeutics Inc.Earnings Growth Report & Entry Point Confirmation Alerts - newser.com
Custom watchlist performance reports with OnKure Therapeutics Inc.2025 Breakouts & Breakdowns & AI Forecast for Swing Trade Picks - newser.com
OnKure Therapeutics Inc.’s volatility index tracking explainedWeekly Stock Summary & Consistent Profit Trade Alerts - newser.com
[EFFECT] OnKure Therapeutics, Inc. SEC Filing - Stock Titan
What momentum shifts mean for OnKure Therapeutics Inc.Weekly Trend Report & Daily Technical Forecast Reports - newser.com
Can you recover from losses in OnKure Therapeutics Inc.2025 Retail Activity & AI Forecasted Stock Moves - newser.com
What valuation multiples suggest for OnKure Therapeutics Inc. stockBond Market & Verified Momentum Stock Watchlist - newser.com
How OnKure Therapeutics Inc. stock compares to market leadersJuly 2025 Chart Watch & Weekly Watchlist for Hot Stocks - newser.com
Finanzdaten der Onkure Therapeutics Inc-Aktie (OKUR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Onkure Therapeutics Inc-Aktie (OKUR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Leverone Jason A. | Chief Financial Officer |
Sep 22 '25 |
Sale |
2.62 |
303 |
795 |
12,603 |
| Saccomano Nicholas A | President and CEO |
Jun 23 '25 |
Sale |
2.38 |
88 |
210 |
3,594 |
| Leverone Jason A. | Chief Financial Officer |
Jun 23 '25 |
Sale |
2.38 |
303 |
722 |
12,906 |
| Cormorant Asset Management, LP | Former 10% Owner |
May 15 '25 |
Sale |
1.85 |
1,813,439 |
3,363,023 |
0 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
1,129,730 |
2,090,000 |
1,129,730 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
270,270 |
500,000 |
1,709,944 |
| Cormorant Asset Management, LP | 10% Owner |
May 12 '25 |
Sale |
1.99 |
24,300 |
48,236 |
1,813,439 |
| Saccomano Nicholas A | President and CEO |
Apr 07 '25 |
Sale |
2.67 |
516 |
1,378 |
3,682 |
| Saccomano Nicholas A | President and CEO |
Apr 04 '25 |
Sale |
3.33 |
358 |
1,191 |
4,198 |
| Leverone Jason A. | Chief Financial Officer |
Apr 07 '25 |
Sale |
2.67 |
1,844 |
4,925 |
13,209 |
0.56%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):